Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Financial & Operational Highlights

  • Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million)
  • Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56.7 million)
  • EBITDA for the Group reached USD 7.4 million (9M 2024: USD 1.6 million)
  • Adjusted EBITDA* arrived at USD 12.2 million, after adjusting import tariffs of around USD 0.7 million, resulting in a margin of 12.1% (9M 2024: 6.5 million at 11.3%)
  • As of September 30, 2025, the Group’s cash position increased to USD 20.0 million (June 30, 2025: USD 18.4 million) despite continued investments in net-working capital, transformation and strategic growth initiatives

Regulatory, Commercial & Clinical Highlights

  • Kuros Biosciences initiated the full commercial launch of MagnetOs™ MIS Delivery System in the U.S. following FDA clearance and successful initial cases, establishing a new standard in minimally invasive advanced graft delivery with a mechanism of action supported by Level I clinical evidence1
  • Kuros received Saudi Food and Drug Authority (SFDA) approval for MagnetOs Putty and MagnetOs Granules in Saudi Arabia, a key milestone in Kuros’s Middle East and North Africa (MENA) expansion and approval by one of the region’s most rigorous regulatory authorities

Outlook

  • As in the previous year, the Group expects sales in the second half of the year in line with usual seasonal trends. Accordingly, the Group is raising its sales guidance and now expects growth of at least 70% for 2025

Schlieren (Zürich), Switzerland, October 16, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced its financial performance for the first nine months of 2025. Total group revenue reached USD 101.1 million, up by 77% compared with the same period in 2024. Revenue from Direct MagnetOs product sales rose 76% year-on-year to USD 99.7 million (9M 2024: USD 56.7 million).

The Group achieved an EBITDA of USD 7.4 million for the first nine months of 2025, up from USD 1.6 million in the prior-year period. Excluding tariff, Adjusted EBITDA* amounted to USD 12.2 million (9M 2024: USD 6.5 million), representing a margin of 12.1%. The Group expects the tariff effect to be temporary as it implements mitigation measures such as adapting its supply chain and establishing a new production footprint in the U.S.

Cash and cash equivalent stood at USD 20.0 million, up from USD 18.4 million as of June 30, 2025, despite continued investments in net-working capital, transformation and strategic growth initiatives.

Following U.S. FDA clearance and the successful completion of initial U.S. cases earlier this year, Kuros has now commenced the full commercial launch of the MagnetOs MIS Delivery System. Purpose-built for minimally invasive spine procedures, MagnetOs MIS is the only prefilled, sterile, human tissue–free bone graft delivery system with a mechanism of action that is backed by Level I clinical evidence.1,2 The system delivers MagnetOs efficiently and precisely into hard-to-reach spaces – three times faster than traditional funnel-based delivery methods – offering surgeons a new standard in handling and reliability for minimally invasive surgery.3,4 The system debuted at the Society for Minimally Invasive Spine Surgery (SMISS) 2025 Annual Meeting, where Dr. Matthew Maserati presented early clinical experience highlighting its ease of use and performance in his MIS fusion procedures.

MagnetOs Putty and MagnetOs Granules were recently approved by the SFDA, marking a major milestone in Kuros’s strategic expansion across the MENA region. As one of the most rigorous regulatory bodies within the Gulf Cooperation Council (GCC), SFDA approval represents a key demonstration of trust in the safety and quality of MagnetOs. Saudi Arabia represents a significant growth opportunity for Kuros.

This approval paves the way for broader access to MagnetOs in one of the region’s most influential markets and underscores Kuros’s commitment to delivering proven, next-generation bone graft solutions worldwide.

Chris Fair, Chief Executive Officer of Kuros Biosciences, stated: “Kuros has recorded a 77% increase in revenue over the first nine months of 2025, marking a significant milestone in our continued expansion. Strong EBITDA underpins our dedication to strategic investment and qualitative growth, with an emphasis on organic development initiatives. Our key growth drivers – including ongoing execution in the spinal market, the launch of innovative technologies like MIS, and expansion into new regions such as extremities and Saudi Arabia – position us to achieve sustained, high-quality growth and deliver lasting value to patients, healthcare professionals, and shareholders around the world.”

back